Summary
The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism.
The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, clearance and volume of distribution) of theophylline 3.4 mg/kg as an intravenous infusion over 5 min (a dosage previously used to test drug interactions with cimetidine and ranitidine) were evaluated in 7 patients with chronic obstructive pulmonary disease (COPD) and peptic ulcer disease before and after 8 days’ treatment with famotidine 40mg at night. The results indicate that famotidine can induce substantial and statistically significant slowing of theophylline elimination with a cimetidine-like interaction profile.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baumann JH, Kimmelblatt BJ, Caraccio TR, Silvermann HM, Simon GI, et al. Cimetidine-theophylline interaction: report of four patients. Annals of Allergy 48: 100–102, 1982
Breen KJ, Bury R, Desmond PV, Mashford ML, Morphett B, et al. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clinical Pharmacology and Therapeutics 31: 297–300, 1982
Dal Negro R, Pomari C, Zoccatelli D, Trevisan F, Carloni C, et al. Pharmacokinetics of theophylline and H2-antagonist drugs cimetidine and ranitidine. International Journal of Clinical Pharmacology Therapy and Toxicology 22(4): 221–226, 1984
Dal Negro R, Pomari C, Zoccatelli D, Trevisan F, Carloni C, et al. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic disease. British Journal of Clinical Practice 41: 1004–1008, 1987
Dal Negro R, Turco P, Pomari C, Trevisan F. Famotidina e teofillina: interferenza farmacocinetica cimetidino-simile? International Journal of Chest Diseases 42: 185–186, 1988
Imai Y, Inada M, Tamura S, Kawata S, Minami Y, et al. Comparative effects of famotidine and cimetidine on 7-ethoxycoumarin O-deethylase activity in human livers. British Journal of Clinical Pharmacology 22: 495, 1986
Jonkman JHG. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. Journal of Allergy and Clinical Immunology 78: 736–742, 986
Klotz U, Arveda P, Rosenkranz B. Famotidine, a new H2 receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. European Journal of Clinical Pharmacology 28: 671–675, 1985
Mitenko PA, Ogilvie RI. Pharmacokinetics of intravenous theophylline. Clinical Pharmacology and Therapeutics 4: 509–513, 1973
Quanjer P. Standardised lung function testing. Bulletin of European Phytopathology and Respiration 19 (Suppl. 5): 7–49, 1983
Somerville KW, Kitchingman GA, Langman MS. Effect of famotidine on oxidative drug metabolism. European Journal of Clinical Pharmacology 30: 279–281, 1986
Von Staieger C, Koroknay B, De Vries JX, Weber E, Muller P, et al. Vergleichende Untersuchungen über den Einfluss von Famotidin und Cimetidin auf die Antypirin-Pharmakokinetik beim Menschen. Arzneimittel-Forschung 34: 1041–1042, 1984
Verdiani P, Di Carlo S, Baronti A. Famotidine effects on the theophylline pharmacokinetics in subjects affected by COPD. Chest 94: 807–810, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dal Negro, R., Pomari, C. & Turco, P. Famotidine and Theophylline Pharmacokinetics. Clin. Pharmacokinet. 24, 255–258 (1993). https://doi.org/10.2165/00003088-199324030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199324030-00006